Cargando…

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tonk, Erwin H.J., van Lindert, Anne S.R., Verhoeff, Joost J.C., Suijkerbuijk, Karijn P.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738224/ https://www.ncbi.nlm.nih.gov/pubmed/31543778 http://dx.doi.org/10.1159/000502202

Ejemplares similares

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis
por: Huang, Sherri, et al.
Publicado: (2022)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Dose-dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy
por: Nagtegaal, Steven H.J., et al.
Publicado: (2020)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients: A case series
por: de Bock, Ellen, et al.
Publicado: (2022)

Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy
por: Maetani, Tomoki, et al.
Publicado: (2021)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
por: León Mengíbar, Jose, et al.
Publicado: (2019)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Factors to Weigh in While Administering Nitrous Oxide Anesthesia [Letter]
por: Shuja, Muhammad Hamza, et al.
Publicado: (2022)

The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
por: Yang, Zhenyi, et al.
Publicado: (2023)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report
por: Wen, Yan-Ping, et al.
Publicado: (2022)

Is double-blinding possible while administering fluids in the intensive care unit?
por: Durukan, Ahmet Baris, et al.
Publicado: (2013)

Factors to Weigh in While Administering Nitrous Oxide Anesthesia [Response to Letter]
por: Sasajima, Hirofumi, et al.
Publicado: (2022)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Durvalumab: First report of minimal change disease: case report
Publicado: (2022)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study
por: Tomassen, Mathijs L., et al.
Publicado: (2021)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Drug-induced sleep endoscopy while administering CPAP therapy in patients with CPAP failure
por: Dieleman, E., et al.
Publicado: (2020)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis
por: Holman, Sarah K., et al.
Publicado: (2017)

Comparison of Different Promoter Methylation Assays in Breast Cancer
por: Suijkerbuijk, Karijn P. M., et al.
Publicado: (2010)

FRI508 A Case Of Durvalumab Induced Hypothyroidism
por: Cecilio La Riva, Estefania Del Valle, et al.
Publicado: (2023)

Radiotherapy Late Effects and Osteogenesis Imperfecta: Dos and Don'ts in Clinical Practice
por: Lodeweges, Joyce E., et al.
Publicado: (2019)

The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Tomassen, Mathijs L., et al.
Publicado: (2022)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u54pmskjdodg75ihiv0r7o7o3c